Concepts (236)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tuberculosis, Multidrug-Resistant | 33 | 2024 | 226 | 5.950 |
Why?
|
| Antitubercular Agents | 27 | 2025 | 322 | 4.120 |
Why?
|
| Diarylquinolines | 15 | 2025 | 39 | 3.820 |
Why?
|
| Extensively Drug-Resistant Tuberculosis | 8 | 2022 | 20 | 3.260 |
Why?
|
| Linezolid | 7 | 2025 | 22 | 2.210 |
Why?
|
| Nitroimidazoles | 7 | 2024 | 24 | 2.170 |
Why?
|
| Tuberculosis | 15 | 2024 | 543 | 1.820 |
Why?
|
| Mycobacterium tuberculosis | 11 | 2024 | 329 | 1.400 |
Why?
|
| Rifampin | 17 | 2024 | 197 | 1.310 |
Why?
|
| Tuberculosis, Pulmonary | 6 | 2024 | 324 | 1.290 |
Why?
|
| HIV Infections | 33 | 2024 | 5097 | 1.230 |
Why?
|
| Humans | 67 | 2025 | 14537 | 1.140 |
Why?
|
| Anti-HIV Agents | 16 | 2019 | 1324 | 1.080 |
Why?
|
| Adult | 42 | 2024 | 5913 | 1.050 |
Why?
|
| Treatment Outcome | 19 | 2024 | 889 | 1.030 |
Why?
|
| Drug Therapy, Combination | 13 | 2024 | 279 | 0.990 |
Why?
|
| Electrocardiography | 2 | 2024 | 35 | 0.960 |
Why?
|
| Female | 44 | 2024 | 9103 | 0.920 |
Why?
|
| Male | 35 | 2024 | 6754 | 0.890 |
Why?
|
| Drug Resistance, Viral | 5 | 2019 | 278 | 0.810 |
Why?
|
| Middle Aged | 18 | 2024 | 3601 | 0.790 |
Why?
|
| South Africa | 34 | 2024 | 7596 | 0.740 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2022 | 11 | 0.640 |
Why?
|
| Viral Load | 5 | 2019 | 819 | 0.560 |
Why?
|
| Ritonavir | 5 | 2016 | 137 | 0.480 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2025 | 7 | 0.480 |
Why?
|
| Liver Transplantation | 3 | 2019 | 55 | 0.460 |
Why?
|
| Young Adult | 12 | 2024 | 2498 | 0.460 |
Why?
|
| Levofloxacin | 3 | 2025 | 21 | 0.460 |
Why?
|
| Clofazimine | 3 | 2025 | 8 | 0.450 |
Why?
|
| Fluoroquinolones | 3 | 2022 | 20 | 0.410 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 2 | 2011 | 33 | 0.400 |
Why?
|
| Pyrazinamide | 2 | 2024 | 14 | 0.400 |
Why?
|
| Killer Cells, Natural | 1 | 2011 | 52 | 0.380 |
Why?
|
| Living Donors | 3 | 2019 | 20 | 0.360 |
Why?
|
| Cost-Benefit Analysis | 5 | 2024 | 253 | 0.360 |
Why?
|
| Adolescent | 10 | 2024 | 2985 | 0.350 |
Why?
|
| Pyrimidinones | 3 | 2011 | 24 | 0.350 |
Why?
|
| Anti-Retroviral Agents | 5 | 2019 | 551 | 0.330 |
Why?
|
| Cohort Studies | 6 | 2022 | 967 | 0.330 |
Why?
|
| Reproducibility of Results | 3 | 2025 | 217 | 0.330 |
Why?
|
| Nevirapine | 3 | 2016 | 146 | 0.290 |
Why?
|
| CD4 Lymphocyte Count | 7 | 2022 | 656 | 0.280 |
Why?
|
| World Health Organization | 3 | 2024 | 137 | 0.280 |
Why?
|
| HIV-1 | 5 | 2011 | 1260 | 0.260 |
Why?
|
| Microbial Sensitivity Tests | 6 | 2023 | 198 | 0.250 |
Why?
|
| Antiretroviral Therapy, Highly Active | 5 | 2016 | 472 | 0.250 |
Why?
|
| Oxazoles | 2 | 2024 | 4 | 0.240 |
Why?
|
| Pregnancy Complications, Infectious | 4 | 2016 | 529 | 0.240 |
Why?
|
| Recurrence | 1 | 2024 | 29 | 0.240 |
Why?
|
| Dried Blood Spot Testing | 1 | 2025 | 24 | 0.240 |
Why?
|
| Long QT Syndrome | 1 | 2024 | 2 | 0.230 |
Why?
|
| Medication Adherence | 3 | 2024 | 151 | 0.230 |
Why?
|
| Risk Assessment | 2 | 2022 | 225 | 0.230 |
Why?
|
| Milk, Human | 1 | 2024 | 23 | 0.230 |
Why?
|
| Prospective Studies | 7 | 2022 | 1160 | 0.220 |
Why?
|
| Lopinavir | 4 | 2016 | 137 | 0.220 |
Why?
|
| HIV Protease Inhibitors | 1 | 2004 | 92 | 0.220 |
Why?
|
| Intention to Treat Analysis | 2 | 2020 | 21 | 0.210 |
Why?
|
| Cross-Sectional Studies | 6 | 2021 | 1422 | 0.210 |
Why?
|
| Drug Interactions | 2 | 2016 | 31 | 0.210 |
Why?
|
| Aminoglycosides | 1 | 2022 | 5 | 0.210 |
Why?
|
| Drug Administration Schedule | 6 | 2024 | 156 | 0.200 |
Why?
|
| Isoniazid | 3 | 2024 | 110 | 0.200 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 11 | 0.200 |
Why?
|
| Anemia | 1 | 2022 | 41 | 0.200 |
Why?
|
| Sputum | 3 | 2021 | 135 | 0.190 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2021 | 135 | 0.190 |
Why?
|
| Population Surveillance | 3 | 2012 | 325 | 0.190 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 163 | 0.180 |
Why?
|
| Time Factors | 5 | 2024 | 507 | 0.180 |
Why?
|
| Interdisciplinary Communication | 1 | 2020 | 1 | 0.180 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2011 | 118 | 0.180 |
Why?
|
| Drug Costs | 2 | 2018 | 18 | 0.180 |
Why?
|
| Coinfection | 3 | 2024 | 276 | 0.180 |
Why?
|
| Bacterial Load | 1 | 2020 | 32 | 0.170 |
Why?
|
| Administration, Oral | 1 | 2020 | 127 | 0.170 |
Why?
|
| Donor Selection | 1 | 2019 | 7 | 0.160 |
Why?
|
| Liver Diseases | 1 | 2019 | 18 | 0.160 |
Why?
|
| Tissue and Organ Procurement | 1 | 2019 | 14 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 71 | 0.160 |
Why?
|
| Poisson Distribution | 1 | 2018 | 18 | 0.160 |
Why?
|
| Lymphocyte Count | 1 | 2018 | 6 | 0.160 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2018 | 7 | 0.160 |
Why?
|
| Liver Failure | 1 | 2018 | 5 | 0.160 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 104 | 0.160 |
Why?
|
| Chemoprevention | 1 | 2018 | 33 | 0.150 |
Why?
|
| AIDS-Related Opportunistic Infections | 4 | 2019 | 195 | 0.150 |
Why?
|
| Infant | 5 | 2024 | 2244 | 0.150 |
Why?
|
| Retrospective Studies | 2 | 2018 | 799 | 0.150 |
Why?
|
| Public Sector | 1 | 2019 | 82 | 0.150 |
Why?
|
| Pandemics | 1 | 2020 | 296 | 0.150 |
Why?
|
| Tenofovir | 2 | 2016 | 171 | 0.150 |
Why?
|
| Registries | 1 | 2018 | 91 | 0.150 |
Why?
|
| Comorbidity | 1 | 2018 | 188 | 0.140 |
Why?
|
| Incidence | 2 | 2024 | 685 | 0.140 |
Why?
|
| Follow-Up Studies | 4 | 2024 | 370 | 0.140 |
Why?
|
| Mothers | 1 | 2019 | 195 | 0.140 |
Why?
|
| Kerosene | 1 | 1997 | 4 | 0.140 |
Why?
|
| Cost Savings | 1 | 2016 | 7 | 0.140 |
Why?
|
| Office Visits | 1 | 2016 | 6 | 0.140 |
Why?
|
| Child, Preschool | 4 | 2024 | 1748 | 0.140 |
Why?
|
| Case-Control Studies | 1 | 2018 | 480 | 0.140 |
Why?
|
| HIV Seropositivity | 1 | 2019 | 265 | 0.140 |
Why?
|
| Aged | 5 | 2024 | 1740 | 0.140 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2016 | 47 | 0.130 |
Why?
|
| Cross Infection | 1 | 2016 | 52 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2024 | 106 | 0.120 |
Why?
|
| Chromatography, Liquid | 2 | 2025 | 5 | 0.120 |
Why?
|
| Limit of Detection | 2 | 2025 | 14 | 0.120 |
Why?
|
| Clinical Trials as Topic | 2 | 2016 | 112 | 0.120 |
Why?
|
| Drug Monitoring | 2 | 2016 | 55 | 0.120 |
Why?
|
| Transcriptome | 1 | 2014 | 14 | 0.110 |
Why?
|
| Mass Screening | 1 | 2016 | 245 | 0.110 |
Why?
|
| Health Personnel | 1 | 2016 | 231 | 0.110 |
Why?
|
| Isoxazoles | 1 | 2013 | 4 | 0.110 |
Why?
|
| Oxazolidinones | 1 | 2013 | 4 | 0.110 |
Why?
|
| Hyperbilirubinemia | 1 | 2013 | 1 | 0.110 |
Why?
|
| Benzoxazines | 2 | 2011 | 123 | 0.110 |
Why?
|
| Pyridines | 1 | 2013 | 11 | 0.110 |
Why?
|
| Oligopeptides | 1 | 2013 | 16 | 0.110 |
Why?
|
| Kanamycin | 2 | 2024 | 5 | 0.110 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2014 | 151 | 0.110 |
Why?
|
| Child | 3 | 2024 | 2242 | 0.100 |
Why?
|
| Stavudine | 2 | 2011 | 78 | 0.100 |
Why?
|
| Prevalence | 2 | 2013 | 1192 | 0.100 |
Why?
|
| Public Health Administration | 1 | 2012 | 14 | 0.100 |
Why?
|
| Infectious Disease Transmission, Vertical | 3 | 2011 | 472 | 0.100 |
Why?
|
| Risk Factors | 3 | 2024 | 1475 | 0.100 |
Why?
|
| Treatment Failure | 3 | 2010 | 175 | 0.100 |
Why?
|
| Capacity Building | 1 | 2012 | 32 | 0.100 |
Why?
|
| Flow Cytometry | 1 | 2011 | 67 | 0.100 |
Why?
|
| Cytokines | 1 | 2011 | 107 | 0.090 |
Why?
|
| Quality of Life | 2 | 2022 | 177 | 0.090 |
Why?
|
| Circumcision, Male | 1 | 2012 | 99 | 0.090 |
Why?
|
| Health Care Costs | 2 | 2024 | 115 | 0.090 |
Why?
|
| Drug Combinations | 2 | 2016 | 42 | 0.090 |
Why?
|
| Linear Models | 2 | 2025 | 83 | 0.080 |
Why?
|
| Pregnancy | 5 | 2016 | 1862 | 0.080 |
Why?
|
| Family Characteristics | 2 | 2020 | 135 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 293 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 385 | 0.070 |
Why?
|
| Uganda | 2 | 2019 | 197 | 0.060 |
Why?
|
| Prenatal Care | 1 | 2006 | 147 | 0.060 |
Why?
|
| Interferon-gamma Release Tests | 1 | 2024 | 8 | 0.060 |
Why?
|
| Calibration | 1 | 2024 | 2 | 0.060 |
Why?
|
| Solid Phase Extraction | 1 | 2024 | 3 | 0.060 |
Why?
|
| Ethambutol | 1 | 2024 | 9 | 0.060 |
Why?
|
| Guanidines | 1 | 2024 | 8 | 0.060 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2024 | 18 | 0.060 |
Why?
|
| RNA, Viral | 2 | 2018 | 303 | 0.060 |
Why?
|
| Drug Resistance, Multiple, Viral | 1 | 2004 | 16 | 0.060 |
Why?
|
| Double-Blind Method | 1 | 2024 | 272 | 0.060 |
Why?
|
| HIV | 2 | 2018 | 380 | 0.060 |
Why?
|
| Georgia | 1 | 2021 | 4 | 0.050 |
Why?
|
| Philippines | 1 | 2021 | 10 | 0.050 |
Why?
|
| Capreomycin | 1 | 2021 | 3 | 0.050 |
Why?
|
| Ethionamide | 1 | 2021 | 9 | 0.050 |
Why?
|
| Amikacin | 1 | 2021 | 7 | 0.050 |
Why?
|
| Australia | 1 | 2021 | 48 | 0.050 |
Why?
|
| Mutation | 1 | 2023 | 306 | 0.050 |
Why?
|
| Peru | 1 | 2021 | 8 | 0.050 |
Why?
|
| Alkynes | 2 | 2011 | 117 | 0.050 |
Why?
|
| Cyclopropanes | 2 | 2011 | 123 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 435 | 0.040 |
Why?
|
| Genotype | 2 | 2011 | 442 | 0.040 |
Why?
|
| Africa South of the Sahara | 2 | 2011 | 353 | 0.040 |
Why?
|
| Tuberculin Test | 1 | 2020 | 49 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2020 | 133 | 0.040 |
Why?
|
| Hospitalization | 1 | 2022 | 418 | 0.040 |
Why?
|
| Tanzania | 1 | 2019 | 88 | 0.040 |
Why?
|
| Liver | 1 | 2019 | 74 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 101 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2019 | 17 | 0.040 |
Why?
|
| Graft Survival | 1 | 2019 | 40 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2018 | 7 | 0.040 |
Why?
|
| HLA-DR Antigens | 1 | 2018 | 13 | 0.040 |
Why?
|
| Ki-67 Antigen | 1 | 2018 | 13 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2018 | 15 | 0.040 |
Why?
|
| Critical Illness | 1 | 2019 | 44 | 0.040 |
Why?
|
| ROC Curve | 1 | 2018 | 51 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2018 | 111 | 0.040 |
Why?
|
| Markov Chains | 1 | 2018 | 22 | 0.040 |
Why?
|
| DNA, Viral | 1 | 2018 | 165 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2013 | 1479 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 253 | 0.040 |
Why?
|
| Serum Amyloid A Protein | 1 | 2017 | 1 | 0.040 |
Why?
|
| Chemokine CXCL10 | 1 | 2017 | 3 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2017 | 14 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2017 | 6 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 1997 | 24 | 0.040 |
Why?
|
| Medically Underserved Area | 1 | 2016 | 13 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2016 | 23 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2017 | 96 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 188 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2017 | 49 | 0.030 |
Why?
|
| Rural Health | 1 | 1997 | 118 | 0.030 |
Why?
|
| HIV Antibodies | 1 | 2018 | 247 | 0.030 |
Why?
|
| Caregivers | 1 | 1997 | 76 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2016 | 125 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 34 | 0.030 |
Why?
|
| National Health Programs | 1 | 2016 | 78 | 0.030 |
Why?
|
| Biomarkers | 1 | 2017 | 327 | 0.030 |
Why?
|
| Contraception | 1 | 2016 | 90 | 0.030 |
Why?
|
| Support Vector Machine | 1 | 2014 | 5 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2014 | 41 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 60 | 0.030 |
Why?
|
| Bilirubin | 1 | 2013 | 3 | 0.030 |
Why?
|
| Glucuronosyltransferase | 1 | 2013 | 6 | 0.030 |
Why?
|
| Atazanavir Sulfate | 1 | 2013 | 10 | 0.030 |
Why?
|
| Plasma | 1 | 2013 | 39 | 0.030 |
Why?
|
| Thymidine | 1 | 2011 | 6 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 64 | 0.020 |
Why?
|
| Nigeria | 1 | 2011 | 49 | 0.020 |
Why?
|
| Lamivudine | 1 | 2011 | 89 | 0.020 |
Why?
|
| Zambia | 1 | 2011 | 115 | 0.020 |
Why?
|
| Zimbabwe | 1 | 2011 | 120 | 0.020 |
Why?
|
| Pacific Islands | 1 | 2010 | 2 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2011 | 31 | 0.020 |
Why?
|
| Kenya | 1 | 2011 | 183 | 0.020 |
Why?
|
| Africa | 1 | 2012 | 376 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 38 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2010 | 12 | 0.020 |
Why?
|
| Therapeutic Equipoise | 1 | 2010 | 4 | 0.020 |
Why?
|
| Asia | 1 | 2010 | 72 | 0.020 |
Why?
|
| Emtricitabine | 1 | 2010 | 78 | 0.020 |
Why?
|
| Organophosphonates | 1 | 2010 | 45 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2010 | 89 | 0.020 |
Why?
|
| Physicians | 1 | 2010 | 31 | 0.020 |
Why?
|
| Adenine | 1 | 2010 | 91 | 0.020 |
Why?
|
| Developing Countries | 1 | 2012 | 400 | 0.020 |
Why?
|
| Withholding Treatment | 1 | 2009 | 26 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2009 | 468 | 0.020 |
Why?
|
| Hospitals | 1 | 2006 | 103 | 0.020 |
Why?
|
| Zinc | 1 | 1960 | 10 | 0.010 |
Why?
|
| Copper | 1 | 1958 | 15 | 0.010 |
Why?
|